FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617148967> ?p ?o ?g. }

• W2617148967 abstract "'Clinically important deterioration' (CID) is a composite endpoint measuring worsening of the key clinical features of chronic obstructive pulmonary disease (COPD), namely lung function, patient-reported outcomes, and exacerbations. ACLIFORM and AUGMENT were two 24-week, randomized, double-blind, phase III studies assessing twice-daily (BID) aclidinium bromide (AB) 400 μg/formoterol fumarate (FF) 12 μg. This pooled post-hoc analysis assessed the effects of AB/FF 400/12 μg on both first and sustained CID events versus placebo and monotherapies in patients with moderate to severe COPD.A first CID event was defined as the occurrence of a moderate/severe exacerbation or the worsening from baseline in ≥1 of the following: trough forced expiratory volume in 1 second (FEV1; ≥100 mL), Transition Dyspnea Index (TDI) focal score (≥1 unit), or St George's Respiratory Questionnaire (SGRQ) total score (≥4 units). A 'sustained' CID was defined as a worsening maintained at all subsequent visits from appearance to week 24 or a moderate/severe exacerbation at any time. CID events were assessed at three visits (weeks 4, 12, and 24); trough FEV1 was also measured at weeks 1 and 18.AB/FF 400/12 μg reduced the risk of a first CID event by 45% versus placebo (hazard ratio [HR] 0.55, p < 0.001), 18% versus FF 12 μg (HR 0.82, p < 0.01), and 15% versus AB 400 μg (HR 0.85, p < 0.05). Similarly, AB/FF 400/12 μg reduced the risk of a sustained CID event by 48% versus placebo (HR 0.52, p < 0.001) and 22% versus FF 12 μg (HR 0.78, p < 0.01). AB/FF 400/12 μg reduced the risk of a first or sustained CID event for all four components versus placebo (trough FEV1 and TDI, first and sustained CID, all p < 0.001; SGRQ first CID p < 0.001; SGRQ sustained CID, p < 0.01; exacerbations first and sustained CID, both p < 0.05) and TDI and SGRQ versus FF 12 μg (TDI, first and sustained CID both p < 0.05; SGRQ first CID p < 0.01), and SGRQ versus AB 400 μg (first CID, p < 0.05).AB/FF 400/12 μg BID may provide greater airway stability and fewer exacerbations or deteriorations in lung function, health status, or dyspnea compared with placebo or monotherapies.Clinicaltrials.gov NCT01462942 (ACLIFORM); registered 26 October 2011. Clinicaltrials.gov NCT01437397 (AUGMENT); registered 19 September 2011." @default.
• W2617148967 created "2017-06-05" @default.
• W2617148967 creator A5003702263 @default.
• W2617148967 creator A5004797506 @default.
• W2617148967 creator A5038136376 @default.
• W2617148967 creator A5061444284 @default.
• W2617148967 creator A5068917661 @default.
• W2617148967 date "2017-05-30" @default.
• W2617148967 modified "2023-10-16" @default.
• W2617148967 title "Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol" @default.
• W2617148967 cites W2009498514 @default.
• W2617148967 cites W2030987445 @default.
• W2617148967 cites W2056040906 @default.
• W2617148967 cites W2082855236 @default.
• W2617148967 cites W2105402505 @default.
• W2617148967 cites W2112433656 @default.
• W2617148967 cites W2122286642 @default.
• W2617148967 cites W2123850585 @default.
• W2617148967 cites W2128643475 @default.
• W2617148967 cites W2134820467 @default.
• W2617148967 cites W2146120854 @default.
• W2617148967 cites W2163229697 @default.
• W2617148967 cites W2170660418 @default.
• W2617148967 cites W2467721645 @default.
• W2617148967 cites W2580357067 @default.
• W2617148967 doi "https://doi.org/10.1186/s12931-017-0583-0" @default.
• W2617148967 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5450266" @default.
• W2617148967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28558833" @default.
• W2617148967 hasPublicationYear "2017" @default.
• W2617148967 type Work @default.
• W2617148967 sameAs 2617148967 @default.
• W2617148967 citedByCount "28" @default.
• W2617148967 countsByYear W26171489672018 @default.
• W2617148967 countsByYear W26171489672019 @default.
• W2617148967 countsByYear W26171489672020 @default.
• W2617148967 countsByYear W26171489672021 @default.
• W2617148967 countsByYear W26171489672022 @default.
• W2617148967 crossrefType "journal-article" @default.
• W2617148967 hasAuthorship W2617148967A5003702263 @default.
• W2617148967 hasAuthorship W2617148967A5004797506 @default.
• W2617148967 hasAuthorship W2617148967A5038136376 @default.
• W2617148967 hasAuthorship W2617148967A5061444284 @default.
• W2617148967 hasAuthorship W2617148967A5068917661 @default.
• W2617148967 hasBestOaLocation W26171489671 @default.
• W2617148967 hasConcept C126322002 @default.
• W2617148967 hasConcept C142724271 @default.
• W2617148967 hasConcept C168563851 @default.
• W2617148967 hasConcept C203092338 @default.
• W2617148967 hasConcept C204787440 @default.
• W2617148967 hasConcept C207103383 @default.
• W2617148967 hasConcept C27081682 @default.
• W2617148967 hasConcept C2776042228 @default.
• W2617148967 hasConcept C2776136866 @default.
• W2617148967 hasConcept C2776780178 @default.
• W2617148967 hasConcept C2776968687 @default.
• W2617148967 hasConcept C2777014857 @default.
• W2617148967 hasConcept C2777714996 @default.
• W2617148967 hasConcept C2779871671 @default.
• W2617148967 hasConcept C3018587741 @default.
• W2617148967 hasConcept C42219234 @default.
• W2617148967 hasConcept C44249647 @default.
• W2617148967 hasConcept C67761136 @default.
• W2617148967 hasConcept C71924100 @default.
• W2617148967 hasConceptScore W2617148967C126322002 @default.
• W2617148967 hasConceptScore W2617148967C142724271 @default.
• W2617148967 hasConceptScore W2617148967C168563851 @default.
• W2617148967 hasConceptScore W2617148967C203092338 @default.
• W2617148967 hasConceptScore W2617148967C204787440 @default.
• W2617148967 hasConceptScore W2617148967C207103383 @default.
• W2617148967 hasConceptScore W2617148967C27081682 @default.
• W2617148967 hasConceptScore W2617148967C2776042228 @default.
• W2617148967 hasConceptScore W2617148967C2776136866 @default.
• W2617148967 hasConceptScore W2617148967C2776780178 @default.
• W2617148967 hasConceptScore W2617148967C2776968687 @default.
• W2617148967 hasConceptScore W2617148967C2777014857 @default.
• W2617148967 hasConceptScore W2617148967C2777714996 @default.
• W2617148967 hasConceptScore W2617148967C2779871671 @default.
• W2617148967 hasConceptScore W2617148967C3018587741 @default.
• W2617148967 hasConceptScore W2617148967C42219234 @default.
• W2617148967 hasConceptScore W2617148967C44249647 @default.
• W2617148967 hasConceptScore W2617148967C67761136 @default.
• W2617148967 hasConceptScore W2617148967C71924100 @default.
• W2617148967 hasIssue "1" @default.
• W2617148967 hasLocation W26171489671 @default.
• W2617148967 hasLocation W26171489672 @default.
• W2617148967 hasLocation W26171489673 @default.
• W2617148967 hasLocation W26171489674 @default.
• W2617148967 hasLocation W26171489675 @default.
• W2617148967 hasOpenAccess W2617148967 @default.
• W2617148967 hasPrimaryLocation W26171489671 @default.
• W2617148967 hasRelatedWork W1974247132 @default.
• W2617148967 hasRelatedWork W2083414123 @default.
• W2617148967 hasRelatedWork W2858694987 @default.
• W2617148967 hasRelatedWork W2885268879 @default.
• W2617148967 hasRelatedWork W2973079945 @default.
• W2617148967 hasRelatedWork W2983417283 @default.
• W2617148967 hasRelatedWork W3048175905 @default.
• W2617148967 hasRelatedWork W3109215948 @default.
• W2617148967 hasRelatedWork W810713411 @default.
• W2617148967 hasRelatedWork W1694352168 @default.

• next